Results 91 to 100 of about 10,816 (168)

Waldenström macroglobulinemia with karyotypic aberrations involving both homologous 6q

, 2001
An 84-year-old female presenting with proptosis and hyperviscosity syndrome was found to have Waldenström macroglobulinemia. Karyotypic analysis showed structural chromosomal abnormalities involving both homologous chromosomes 6 with a deleted 6q at q21 ...
So, CC, Wong, KF
core   +1 more source

Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia

Haematologica, 2018
Jorge J. Castillo, Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Patricia Severns, Steven P. Treon   +5 more
doaj   +1 more source

The role of ibrutinib in Waldenström macroglobulinemia

, 2018
Introduction: Waldenström macroglobulinemia (WM) is an uncommon incurable B-cell lymphoma characterized by the presence lymphoplasmacytic cells in the bone marrow.
Gavriatopoulou, Maria, Terpos, Evangelos, Dimopoulos, Meletios Athanasios, Gavriatopoulou, M., Terpos, E., Dimopoulos, M.A., Kastritis, E., Kastritis, Efstathios   +7 more
core   +1 more source

Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia [PDF]

With the increasing availability of sequencing techniques and new polymerase chain reaction-based methods, data regarding the genomic profile of Waldenström macroglobulinemia (WM) are being continuously analyzed and reproduced.
Moreno Fajardo, David Fernando, Fernández de Larrea Rodríguez, Carlos José   +1 more
core   +1 more source

Waldenström Macroglobulinemia and Cerebral Venous Thrombosis: From Diagnosis to Complication

, 2019
Waldenström macroglobulinemia (WM) is a type of non-Hodgkin lymphoma in which cancer cells produce large amounts of an abnormal protein that can cause hyperviscosity syndrome (HVS). A 43-year-old woman with WM, who developed seizures, had a head computed
Pedro Vieira, Orlando Mendes, Andreia Póvoa, Heidy Cabrera, Céu Evangelista, Pedro Chorão, Paulo Zoé Costa   +6 more
core   +1 more source

Assessment of Treatment Response in Patients Diagnosed with Waldenström’s Macroglobulinemia: Single-Center Experience

Uludağ Üniversitesi Tıp Fakültesi Dergisi
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma characterized by the production of monoclonal IgM. It may lead to symptoms such as hyperviscosity syndrome, anemia, and neuropathy.
Şeyma Yavuz, Vildan Ozkocaman, Vildan Gürsoy, Tuba Ersal, İbrahim Ethem Pınar, Fazıl Cagrı Hunutlu, Ezel Elgun, Fahir Özkalemkaş   +7 more
doaj   +1 more source

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia

International audienceAbstract Histologic transformation of Waldenström macroglobulinemia (HT-WM) carries a poor prognosis with standard treatments. Here, we report the first series of HT-WM treated with chimeric antigen receptor T cells showing a high ...
Decroocq, Justine, Bensaber, Hedi, Delmer, Alain, Gastinne, Thomas, Roos-Weil, Damien, Bachy, Emmanuel, Cheminant, Morgane, Jacquet, Caroline, Chauchet, Adrien, Houot, Roch, Reshef, Ran, Le Gouill, Steven, Cony-Makhoul, Pascale, Treon, Steven, Gros, François-Xavier, Durot, Eric, Coste, Arthur, Castillo, Jorge, Guidez, Stéphanie, Di Blasi, Roberta   +19 more
core   +1 more source

Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells

Blood Advances
Dominic Pizzarella, Amanda Kofides, John M. Hatcher, Xia Liu, Alberto Guijosa, Nickolas Tsakmaklis, Abigail L. Peachey, Jinhua Wang, Maria Luisa Guerrera, Christopher J. Patterson, Zachary R. Hunter, Hao Sun, Shayna R. Sarosiek, Jorge J. Castillo, Sara J. Buhrlage, Sirano Dhe-Paganon, Andrew R. Branagan, Steven P. Treon, Shirong Liu   +18 more
doaj   +1 more source

Refining prognostic tools in Waldenström macroglobulinemia. [PDF]

Blood Adv
Lionel AC, Thomas SK.
europepmc   +1 more source

The impact of chemoimmunotherapy on primary cold agglutinin disease and Waldenström macroglobulinemia-associated cold agglutinin syndrome. [PDF]

Front Med (Lausanne)
Ito K, Kitagawa T, Motohashi S, Hirano K, Sekiguchi N.   +4 more
europepmc   +1 more source